Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adult subjects aged 18 to 50 years inclusive, who are able and willing to give informed consent, following a detailed explanation of participation in protocol~* available for the duration of the study and available for scheduled and potential additional visits~Exclusion Criteria:~* women who are pregnant, breast-feeding or of childbearing potential and unwilling to use a reliable method of contraception throughout the study period~* history of anaphylactic shock following vaccination by any route have phenylketonuria~* hypersensitivity to any component of the vaccine or are hypersensitive to two of the following antibiotics: ciprofloxacin, azithromycin, ampicillin, trimethoprim sulfamethoxazole~* received antibiotic medication within 14 days prior to dosing~* received any vaccine within 4 weeks prior to dosing or plan to receive a vaccine within 4 weeks after dosing~* received any vaccine against Salmonella typhi (licensed or investigational) or ever suffered from typhoid fever~* subjects who test positive for hepatitis B, hepatitis C, HIV or human leucocyte antigen B-27~* known or suspected history of liver or active gall bladder disease, ongoing gastro-intestinal disease or abnormality~* commercial food handlers or health care workers with direct contact with high risk patients or who have household contacts with immuno-compromised individuals, pregnant women or children less than 2 years of age~* subjects who have a clinically significant amount of protein or haemoglobin in their urine or abnormality of their haematology or serum biochemistry parameters~* impairment of immune function or those receiving or have received cytotoxic drugs in the 6 months prior to study entry~* subjects who use antacids, proton pump inhibitors or H2 blockers on a regular basis or have consumed proton pump inhibitors or H2 blockers within 24 hours prior to dosing~* acute infections (including fever of 37.5 degrees Celsius or greater) on the day of dosing.~* subjects with chronic disease (e.g Crohn's disease, inflammatory bowel disease, diabetes) who cannot withstand a 3 hour fast~* substance abuse or a history of substance abuse that might interfere with participation in the study~* body mass index (BMI) is less than 19 or greater than 34 kg per m2~* clinically significant medical condition that precludes participation in the study~* subjects who have participated in an interventional clinical trial within 60 days of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- M01ZH09 Vaccine Candidate Cohort 1 (Type: EXPERIMENTAL): Dose of 5.0 x 10\^9 colony forming units (CFU) S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
- M01ZH09 Vaccine Candidate Cohort 2 (Type: EXPERIMENTAL): Dose of 7.5 x 10\^9 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
- M01ZH09 Vaccine Candidate Cohort 3 (Type: EXPERIMENTAL): Dose of 1.1 x 10\^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
- M01ZH09 Vaccine Candidate Cohort 4 (Type: EXPERIMENTAL): Dose of of 1.7 x 10\^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).